Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 9

1.

ADAMTS13 predicts renal and cardiovascular events in type 2 diabetic patients and response to therapy.

Rurali E, Noris M, Chianca A, Donadelli R, Banterla F, Galbusera M, Gherardi G, Gastoldi S, Parvanova A, Iliev I, Bossi A, Haefliger C, Trevisan R, Remuzzi G, Ruggenenti P; BENEDICT Study Group.

Diabetes. 2013 Oct;62(10):3599-609. doi: 10.2337/db13-0530. Epub 2013 Jun 3.

PMID:
23733198
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes.

Ruggenenti P, Porrini E, Motterlini N, Perna A, Ilieva AP, Iliev IP, Dodesini AR, Trevisan R, Bossi A, Sampietro G, Capitoni E, Gaspari F, Rubis N, Ene-Iordache B, Remuzzi G; BENEDICT Study Investigators.

J Am Soc Nephrol. 2012 Oct;23(10):1717-24. Epub 2012 Aug 30.

PMID:
22935482
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial.

Ruggenenti P, Fassi A, Ilieva A, Iliev IP, Chiurchiu C, Rubis N, Gherardi G, Ene-Iordache B, Gaspari F, Perna A, Cravedi P, Bossi A, Trevisan R, Motterlini N, Remuzzi G; BENEDICT-B Study Investigators.

J Hypertens. 2011 Feb;29(2):207-16.

PMID:
21243736
[PubMed - indexed for MEDLINE]
4.

Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT.

De Cosmo S, Motterlini N, Prudente S, Pellegrini F, Trevisan R, Bossi A, Remuzzi G, Trischitta V, Ruggenenti P; BENEDICT Study Group.

Diabetes. 2009 Dec;58(12):2920-9. doi: 10.2337/db09-0407. Epub 2009 Aug 31.

PMID:
19720797
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

72-hour epidural infusion of 0.125% levobupivacaine following total knee replacement: a prospective, randomized, controlled, multicenter evaluation.

Casati A, Ostroff R, Casimiro C, Faluhelyi A, Medina J, Fanelli G; Chiropolis Study Group.

Acta Biomed. 2008 Apr;79(1):28-35.

PMID:
18551819
[PubMed - indexed for MEDLINE]
Free Article
6.

The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial.

Ametov AS, Barinov A, Dyck PJ, Hermann R, Kozlova N, Litchy WJ, Low PA, Nehrdich D, Novosadova M, O'Brien PC, Reljanovic M, Samigullin R, Schuette K, Strokov I, Tritschler HJ, Wessel K, Yakhno N, Ziegler D; SYDNEY Trial Study Group.

Diabetes Care. 2003 Mar;26(3):770-6. Erratum in: Diabetes Care. 2003 Jul;26(7):2227.

PMID:
12610036
[PubMed - indexed for MEDLINE]
7.

Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy.

Ruhnau KJ, Meissner HP, Finn JR, Reljanovic M, Lobisch M, Schütte K, Nehrdich D, Tritschler HJ, Mehnert H, Ziegler D.

Diabet Med. 1999 Dec;16(12):1040-3.

PMID:
10656234
[PubMed - indexed for MEDLINE]
8.

Double-blind, placebo-controlled cross-over study of intravenous S-adenosyl-L-methionine in patients with fibromyalgia.

Volkmann H, Nørregaard J, Jacobsen S, Danneskiold-Samsøe B, Knoke G, Nehrdich D.

Scand J Rheumatol. 1997;26(3):206-11.

PMID:
9225876
[PubMed - indexed for MEDLINE]
9.

[Effectiveness of flupirtine in chronic tension headache. Results of a double-blind study versus placebo].

Wörz R, Lobisch M, Schwittmann B, Gessler M, Grotemeyer KH, Langohr HD, Lüben V, May A, Nehrdich D, Schabet M, et al.

Fortschr Med. 1995 Nov 20;113(32):463-8. German. No abstract available.

PMID:
8543273
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk